# OnCo record oprelvekin (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/oprelvekin/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "oprelvekin" ;
  schema:name "Oprelvekin"@en ;
  schema:alternateName "Recombinant interleukin-11"@en, "rhIL-11"@en, "Neumega" ;
  schema:description "Oprelvekin was the first drug approved, in 1997, to prevent the severe platelet falls that chemotherapy causes, but fluid retention and heart rhythm problems limited it and it was withdrawn in 2011; thrombopoietin agonists took over the problem."@en ;
  schema:url <https://onco.cc/drugs/oprelvekin/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Oprelvekin> ;
  schema:citation <https://en.wikipedia.org/wiki/Oprelvekin>, <https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL1201564> ;
  onco:status "withdrawn" ;
  onco:tag "gap-fill", "chembl-universe" ;
  onco:modality "Recombinant interleukin-11, subcutaneous injection" ;
  onco:approval "US 1997: Prevention of severe thrombocytopenia and reduction of platelet transfusions after myelosuppressive chemotherapy in non-myeloid malignancies" ;
  onco:technologies <https://onco.cc/technologies/cytokine-therapy/> ;
  onco:targets <https://onco.cc/targets/il11ra/> ;
  onco:drugs <https://onco.cc/drugs/romiplostim/>, <https://onco.cc/drugs/eltrombopag/> ;
  onco:companies <https://onco.cc/companies/pfizer/> ;
  onco:trials <https://onco.cc/trials/nct00493181/>, <https://onco.cc/trials/nct00004157/> .